Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
RPRX

RPRX - Royalty Pharma PLC Stock Price, Fair Value and News

31.02USD-0.21 (-0.67%)Market Closed
Watchlist

Market Summary

USD31.02-0.21
Market Closed
-0.67%

RPRX Alerts

  • Big jump in Earnings (Y/Y)

RPRX Stock Price

View Fullscreen

RPRX RSI Chart

RPRX Valuation

Market Cap

13.9B

Price/Earnings (Trailing)

12.26

Price/Sales (Trailing)

5.91

EV/EBITDA

10.37

Price/Free Cashflow

4.66

RPRX Price/Sales (Trailing)

RPRX Profitability

EBT Margin

72.20%

Return on Equity

11.25%

Return on Assets

6.93%

Free Cashflow Yield

21.48%

RPRX Fundamentals

RPRX Revenue

Revenue (TTM)

2.4B

Rev. Growth (Yr)

5.36%

Rev. Growth (Qtr)

11.14%

RPRX Earnings

Earnings (TTM)

1.1B

Earnings Growth (Yr)

208.39%

Earnings Growth (Qtr)

585.5%

Breaking Down RPRX Revenue

Last 7 days

2.3%

Last 30 days

5.4%

Last 90 days

12.5%

Trailing 12 Months

-21.5%

How does RPRX drawdown profile look like?

RPRX Financial Health

Current Ratio

7.9

Debt/Equity

0.61

Debt/Cashflow

0.49

RPRX Investor Care

Dividend Yield

2.58%

Dividend/Share (TTM)

0.8

Shares Dilution (1Y)

2.08%

Diluted EPS (TTM)

2.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.4B2.4B2.3B2.4B
20222.3B2.3B2.2B2.2B
20212.4B2.4B2.5B2.3B
20201.2B1.6B1.6B1.9B
20191.2B1.4B1.6B1.8B
2018904.2M930.5M956.9M983.2M
2017000877.9M

Tracking the Latest Insider Buys and Sells of Royalty Pharma PLC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 04, 2024
riggs rory b
sold
-983,504
27.5476
-35,702
-
Jan 03, 2024
riggs rory b
sold
-5,532,280
27.7867
-199,098
-
Jan 02, 2024
riggs rory b
sold
-6,707,080
28.5165
-235,200
-
Dec 29, 2023
bassler bonnie l
acquired
37,493
27.711
1,353
-
Dec 29, 2023
fernandez henry a
acquired
37,493
27.711
1,353
-
Dec 29, 2023
avara management ltd
sold
-1,845,410
28.0444
-65,803
-
Dec 28, 2023
avara management ltd
sold
-5,918,930
28.2038
-209,863
-
Dec 27, 2023
avara management ltd
sold
-1,168,750
28.0082
-41,729
-
Dec 15, 2023
avara management ltd
sold
-286,499
28.0085
-10,229
-
Dec 14, 2023
avara management ltd
sold
-10,534,300
28.9053
-364,441
-

1–10 of 50

Which funds bought or sold RPRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Aurora Investment Counsel
added
7.01
556,346
1,585,010
1.03%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
reduced
-46.82
-12,253,200
14,999,400
0.24%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-31.28
-15,604,000
38,433,000
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
10.7
605,761
4,766,760
0.02%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
added
88.43
6,235
12,795
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-79.89
-1,521,000
400,000
0.03%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
reduced
-99.22
-2,767,840
22,472
-%
Feb 15, 2024
Legal & General Group Plc
added
14.63
12,887,900
82,003,800
0.02%
Feb 15, 2024
Tidal Investments LLC
added
23.14
425,400
1,975,150
0.05%
Feb 15, 2024
JANE STREET GROUP, LLC
added
458
9,693,500
11,720,800
-%

1–10 of 44

Are Funds Buying or Selling RPRX?

Are funds buying RPRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RPRX
No. of Funds

Unveiling Royalty Pharma PLC's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.54%
37,997,522
SC 13G/A
Feb 13, 2024
general atlantic, l.p.
5.6%
26,259,141
SC 13G/A
Feb 09, 2024
morgan stanley
9.2%
41,159,749
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 13, 2023
general atlantic, l.p.
5.6%
26,244,741
SC 13G/A
Feb 10, 2023
morgan stanley
9.9%
43,775,398
SC 13G/A
Feb 09, 2023
adage capital partners gp, l.l.c.
1.59%
7e+06
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.08%
35,627,791
SC 13G/A
Oct 04, 2022
giuliani mario germano
2.7%
11,604,660
SC 13D/A

Recent SEC filings of Royalty Pharma PLC

View All Filings
Date Filed Form Type Document
Feb 22, 2024
4
Insider Trading
Feb 15, 2024
10-K
Annual Report
Feb 15, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
8-K
Current Report
Jan 08, 2024
8-K
Current Report
Jan 04, 2024
4
Insider Trading

What is the Fair Value of RPRX?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Royalty Pharma PLC)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Royalty Pharma PLC News

Latest updates
MarketBeat28 minutes ago
Seeking Alpha19 Feb 202404:32 am
InvestorsObserver12 Feb 202408:00 am
InvestorsObserver06 Feb 202408:00 am

Royalty Pharma PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue11.1%596536538684566573536562576586555573759538511128457464156--
Costs and Expenses-104.4%-16.833852892051,048381158342422283-18934425828.00102139-874-68.22130--
  S&GA Expenses3.4%59.0057.0048.0086.0073.0051.0052.0052.0046.0049.0045.0043.0050.0051.0043.0038.0023.0026.0030.00--
  R&D Expenses-99.0%1.0051.001.001.0051.0026.001.00101-91.003.003.008.005.006.008.0016.0023.0021.00--
EBITDA Margin233.1%0.80*0.24*0.28*0.34*0.19*0.48*0.48*0.61*0.61*0.69*0.87*0.79*0.96*1.81*1.81*2.01*1.50*1.12*1.29*1.51*1.83*
Interest Expenses2.7%47.0046.0047.0047.0047.0047.0047.0047.0047.0044.0037.0037.0038.0031.0034.0054.0063.0069.0069.00--
Income Taxes----------------------
Earnings Before Taxes487.8%718122351509-61022049212854.002228071593676246021091,447440179--
EBT Margin350.6%0.72*0.16*0.20*0.26*0.10*0.40*0.40*0.53*0.54*0.63*0.81*0.74*0.88*1.70*1.66*1.80*1.36*0.94*1.09*1.27*1.54*
Net Income585.5%49472.00228341-45614330552.008.0010244169.00495-44238.001,420409152--
Net Income Margin507.5%0.48*0.08*0.11*0.14*0.02*0.23*0.21*0.26*0.27*0.45*0.41*0.42*0.50*1.16*1.48*1.67*1.29*0.86*0.98*1.16*1.40*
Free Cashflow34.7%7735746081,034570539575460490470532526566509489471478419---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets3.3%16,38215,85617,12117,07416,81317,67317,74017,37917,51617,73216,51515,91416,02015,99115,68614,06812,45012,18011,91011,64011,370
  Current Assets-26.3%1,2741,7292,9542,6312,5552,3423,5042,9822,8782,7762,7072,4162,6972,7843,391-832---2,609
    Cash Equivalents-49.1%4779362,1731,9761,7119922,1081,7921,5411,8011,1427091,0091,5532,322498246116593-1,924
Liabilities0.4%6,2986,2707,3087,2527,2887,2567,3327,2377,2677,3466,1106,0776,1246,1926,2916,3006,3086,4366,5636,6916,818
  Current Liabilities26.1%1611281,1721,1171,1671,132182136171255284256308270451-333---580
  Long Term Debt-100.0%-6,1316,1276,1236,1196,1157,1067,1017,0967,0915,8265,8215,8175,8125,730-5,956---6,238
    LT Debt, Current---999998998997--------182-282---281
    LT Debt, Non Current0.1%6,1356,1316,1276,1236,1196,1157,1067,1017,0967,0915,8265,8215,8175,8125,730-5,956---6,238
Shareholder's Equity5.2%10,0849,5859,8149,8229,52510,41610,40810,14210,24910,38710,4059,8379,8969,7999,3957,1636,1414,8954,6534,7054,552
  Retained Earnings17.9%2,5182,1352,2532,2171,9652,5052,4462,2252,2552,3212,2921,9241,9211,8071,571-2,825---1,216
  Additional Paid-In Capital0.1%4,0114,0074,0313,7403,6663,6333,5713,5433,5083,4543,4162,9312,8662,6122,557------
Shares Outstanding-100.0%-448450446438439436434415409400390375370354-37.00---37.00
Minority Interest3.2%3,5583,4463,5323,8683,8974,2644,3814,3644,4724,5944,6724,9555,0775,3475,238-36.00---64.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations34.7%7735746081,034570539575460490470532526566509489471478419---
Cashflow From Investing-121.9%-1,000-450-63.43-558415-1,425-30.1811.00-551-845126-599-832-920-244-761-62.82-615---
Cashflow From Financing82.9%-231-1,359-347-210-265-230-228-220-1981,034-224-226-277-3571,579543-285-280---
  Buy Backs-79.0%30.00144134-------------0.00----

RPRX Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Total income and other revenues$ 2,354,554$ 2,237,215$ 2,289,463
Operating expenses   
Provision for changes in expected cash flows from financial royalty assets560,656904,244452,842
Research and development funding expense52,000177,106200,084
Amortization of intangible assets05,67022,996
General and administrative expenses249,748227,303182,826
Financial royalty asset impairment0615,8270
Total operating expenses, net862,4041,930,150858,748
Operating income1,492,150307,0651,430,715
Other (income)/expense   
Equity in (earnings)/losses of equity method investees(28,882)8,97319,490
Interest expense187,187187,961166,142
Losses/(gains) on derivative financial instruments2,290(96,610)21,532
(Gains)/losses on equity securities(87,139)33,44248,066
(Gains)/losses on available for sale debt securities(230,840)6,815(17,859)
Interest income(72,291)(78,335)(53,535)
Other non-operating expense, net21,73714,7555,678
Total other (income)/expense, net(207,938)77,001189,514
Consolidated net income before tax1,700,088230,0641,241,201
Income tax expense000
Consolidated net income1,700,088230,0641,241,201
Net income attributable to non-controlling interests565,254187,232621,473
Net income attributable to Royalty Pharma plc$ 1,134,834$ 42,832$ 619,728
Earnings per Class A ordinary share:   
Basic (in dollars per share)$ 2.54$ 0.10$ 1.49
Diluted (in dollars per share)$ 2.53$ 0.10$ 1.49
Weighted average Class A ordinary shares outstanding:   
Basic (in shares)447,601437,963414,794
Diluted (in shares)602,900437,972414,802
Income from financial royalty assets   
Total income and other revenues$ 2,197,754$ 2,125,096$ 2,065,083
Revenue from intangible royalty assets   
Total income and other revenues83537,484171,248
Other royalty income   
Total income and other revenues$ 155,965$ 74,635$ 53,132

RPRX Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 477,010$ 1,710,751
Marketable securities024,421
Financial royalty assets738,438691,319
Accrued royalty receivable14,24216,830
Available for sale debt securities18,3001,300
Other royalty income receivable22,40519,767
Other current assets3,79890,520
Total current assets1,274,1932,554,908
Financial royalty assets, net14,088,65513,493,106
Equity securities199,487112,348
Available for sale debt securities437,100226,300
Equity method investments375,894397,175
Other assets6,52229,629
Total assets16,381,85116,813,466
Current liabilities  
Distributions payable to legacy non-controlling interests83,15594,803
Accounts payable and accrued expenses15,1657,906
Interest payable51,68254,162
Current portion of long-term debt0997,512
Other current liabilities11,37512,400
Total current liabilities161,3771,166,783
Long-term debt6,135,2856,118,810
Other liabilities9002,500
Total liabilities6,297,5627,288,093
Commitments and contingencies
Shareholders’ equity  
Deferred shares, $0.000001 par value; issued and outstanding: 2023–384,640 and 2022–371,32500
Additional paid-in capital4,011,4353,666,160
Retained earnings2,517,5831,964,689
Non-controlling interests3,557,7923,897,223
Treasury interests(2,629)(2,806)
Total shareholders’ equity10,084,2899,525,373
Total liabilities and shareholders’ equity16,381,85116,813,466
Class A Ordinary Shares  
Shareholders’ equity  
Common stock4544
Class B Ordinary Shares  
Shareholders’ equity  
Common stock00
Class R Redeemable Shares  
Shareholders’ equity  
Common stock$ 63$ 63
RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
0
 CEO
 WEBSITEwww.royaltypharma.com

Royalty Pharma PLC Frequently Asked Questions


What is the ticker symbol for Royalty Pharma PLC? What does RPRX stand for in stocks?

RPRX is the stock ticker symbol of Royalty Pharma PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Royalty Pharma PLC (RPRX)?

As of Thu Feb 22 2024, market cap of Royalty Pharma PLC is 13.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPRX stock?

You can check RPRX's fair value in chart for subscribers.

What is the fair value of RPRX stock?

You can check RPRX's fair value in chart for subscribers. The fair value of Royalty Pharma PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Royalty Pharma PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RPRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Royalty Pharma PLC a good stock to buy?

The fair value guage provides a quick view whether RPRX is over valued or under valued. Whether Royalty Pharma PLC is cheap or expensive depends on the assumptions which impact Royalty Pharma PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPRX.

What is Royalty Pharma PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, RPRX's PE ratio (Price to Earnings) is 12.26 and Price to Sales (PS) ratio is 5.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPRX PE ratio will change depending on the future growth rate expectations of investors.